Clinical Trial Update: An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating intravenous immunoglobulin (5%) for Primary Immune Thrombocytopenia; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Intravenous Immunoglobulin (5%) (intravenous immunoglobulin)

Snippet

Sponsor: Grand Shuyang Life Sciences (Chengdu) Co., Ltd. | Conditions: Primary Immune Thrombocytopenia (ITP) | Phase 3 | Status: RECRUITING